Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €29.66 EUR
Change Today -0.398 / -1.32%
Volume 312.0
As of 5:17 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

David Tyronne Howton

Senior Vice President, General Counsel and Corporate Secretary, Sarepta Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

As of Fiscal Year 2014


Mr. David Tyronne Howton, also known as Ty, has been an Senior Vice President, Corporate Secretary and General Counsel of Sarepta Therapeutics, Inc. since November 05, 2012. Mr. Howton served as Senior Vice President and Chief Legal Officer of Vertex Pharmaceuticals Incorporated from September 2011 to June 2012 and served as its Secretary and Member of the Executive Team until June 2012. He joined Vertex in 2009. He served in a number of legal roles at Genentech and ...

Read Full Background

Corporate Headquarters*

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 617-274-4000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.


Yale University
Northwestern University School of Law

Other Affiliations*

Annual Compensation*

Total Annual Compensation$393,407

Stock Options*

All Other Compensation$12,518
Exercisable Options95,000
Unexercisable Options155,000
Total Number of Options289,938

Total Compensation*

Total Annual Cash Compensation$539,683
Total Short Term Compensation$393,407
Other Long Term Compensation$12,518
Total Calculated Compensation$1,694,914
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €29.66 EUR -0.398


Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
200.0K GBP
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at